Antoniadis Antonios P, Sieniewicz Ben, Gould Justin, Porter Bradley, Webb Jessica, Claridge Simon, Behar Jonathan M, Rinaldi Christopher Aldo
Cardiovascular Department, Guy's and St Thomas' NHS Foundation Trust, Lower Ground Floor, South Wing, St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, UK.
Curr Heart Fail Rep. 2017 Oct;14(5):376-383. doi: 10.1007/s11897-017-0350-z.
Cardiac resynchronization therapy (CRT) reduces the morbidity and mortality of patients with left ventricular (LV) systolic dysfunction and intra-ventricular conduction delay. However, its clinical outcomes are heterogeneous and not all patients show a beneficial response. Multisite pacing (MSP), by stimulating the myocardium from more than one locations, is a potential therapeutic option in patients requiring CRT. This article provides a current update in the methods and outcomes of MSP, as well as in challenges in this field and opportunities for further research and development.
MSP can be delivered either with multiple leads or with quadripolar LV leads which can stimulate the LV from two separate sites. Initial results are promising but not always consistent across studies. Larger patient subgroups and longer follow-up duration are required for more conclusive evaluation of MSP. Routine use of MSP in clinical practice cannot be advocated at present. In selected patient subgroups, however, MSP could be considered. Newer devices and expanding knowledge are expected to facilitate the more widespread implementation of MSP and the assessment of its effects in the clinical outcomes of CRT.
心脏再同步治疗(CRT)可降低左心室(LV)收缩功能障碍和室内传导延迟患者的发病率和死亡率。然而,其临床结果存在异质性,并非所有患者都表现出有益反应。多部位起搏(MSP)通过从多个位置刺激心肌,是需要CRT的患者的一种潜在治疗选择。本文提供了MSP方法和结果的最新进展,以及该领域的挑战和进一步研发的机会。
MSP可通过多根导线或四极左心室导线进行,后者可从两个不同部位刺激左心室。初步结果令人鼓舞,但各研究结果并不总是一致。需要更大的患者亚组和更长的随访时间来对MSP进行更具结论性的评估。目前不能提倡在临床实践中常规使用MSP。然而,在选定的患者亚组中,可以考虑使用MSP。预计更新的设备和不断扩展的知识将促进MSP更广泛的应用及其对CRT临床结果影响的评估。